Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 173

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Safety and Immunogenicity of a New Tuberculosis Vaccine, MVA85A, in Healthy Adults in South Africa

Open access
Hawkridge, Tony, Scriba, Thomas J., Gelderbloem, Sebastian, Smit, Erica, Tameris, Michele, Moyo, Sizulu, Lang, Trudie, Veldsman, Ashley, Hatherill, Mark, Merwe, Linda van der, Fletcher, Helen A., Mahomed, Hassan, Hill, Adrian V. S., Hanekom, Willem A., Hussey, Gregory D., McShane, Helen · 2008 · The Journal of Infectious Diseases

Abstract

BACKGROUND: The efficacy of bacille Calmette-Guérin (BCG) may be enhanced by heterologous vaccination strategies that boost the BCG-primed immune response. One leading booster vaccine, MVA85A (where "MVA" denotes "modified vaccinia virus Ankara"), has shown promising safety and immunogenicity in human trials performed in the United Kingdom. We investigated the safety and immunogenicity of MVA85A in mycobacteria-exposed--but Mycobacterium tuberculosis-uninfected--healthy adults from a region of South Africa where TB is endemic. METHODS: Twenty-four adults were vaccinated with MVA85A. All subjects were monitored for 1 year for adverse events and for immunological assessment. RESULTS: MVA85A vaccination was well tolerated and induced potent T cell responses, as measured by interferon (IFN)-gamma enzyme-linked immunospot assay, which exceeded prevaccination responses up to 364 days after vaccination. BCG-specific CD4+ T cells boosted by MVA85A were comprised of multiple populations expressing combinations of IFN-gamma, tumor necrosis factor (TNF)-alpha, interleukin (IL)-2, and IL-17, as measured by polychromatic flow cytometry. IFN-gamma-expressing and polyfunctional IFN-gamma+TNF-gamma+IL-2+ CD4+ T cells were boosted during the peak BCG-specific response, which occurred 7 days after vaccination. CONCLUSION: The excellent safety profile and quantitative and qualitative immunogenicity data strongly support further trials assessing the efficacy of MVA85A as a boosting vaccine in countries where TB is endemic. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00460590.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1086/590185

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 173

Metadata

Authors
Hawkridge, T., Scriba, T. J., Gelderbloem, S., Smit, E., Tameris, M., Moyo, S., Lang, T., Veldsman, A., Hatherill, M., Merwe, L. V. D., Fletcher, H. A., Mahomed, H., Hill, A. V. S., Hanekom, W. A., Hussey, G. D., & McShane, H.
Venue
The Journal of Infectious Diseases
Published
2008-08-15
Volume
198
Issue
4
Pages
544-552
ISSN
  • 0022-1899 (ISSN-L)
  • 1537-6613
OpenAlex
W2164794843
Cited by
173
References
3
FWCI
13.04
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and Immunogenicity of a New Tuberculosis Vaccine, MVA85A, in Healthy Adults in South Africa. https://app.cochat.ai/papers/10.1086/590185
The paper
Hawkridge, T., Scriba, T. J., Gelderbloem, S., Smit, E., Tameris, M., Moyo, S., Lang, T., Veldsman, A., Hatherill, M., Merwe, L. V. D., Fletcher, H. A., Mahomed, H., Hill, A. V. S., Hanekom, W. A., Hussey, G. D., & McShane, H. (2008). Safety and Immunogenicity of a New Tuberculosis Vaccine, MVA85A, in Healthy Adults in South Africa. The Journal of Infectious Diseases. https://doi.org/10.1086/590185

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.